Managers / Q1 2025 · view latest →
Tejara Capital Ltd
CIK 0001879713 · 15TH FLOOR, 33 CAVENDISH SQUARE, LONDON, X0, W1G 0PW · 0044(0)2079078566
Summary
Tejara Capital Ltd reported $259M in U.S.-listed holdings across 75 positions for Q1 2025.
Its largest position, ARQT, represents 5.1% of the portfolio.
Compared with Q4 2024, the fund opened 31 new positions and exited 11.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 47.3% · $123M
- Other · 26.5% · $69M
- ETP · 21.7% · $56M
- ADR · 4.5% · $12M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| NDQINVESCO QQQ TR | NEW | +120.0K | 120.0K | +$56M | $56M |
| CNRCORE NATURAL RESOURCES INC | NEW | +82.3K | 82.3K | +$6M | $6M |
| FTAI AVIATION LTD | NEW | +43.0K | 43.0K | +$5M | $5M |
| NFENEW FORTRESS ENERGY INC | NEW | +520.6K | 520.6K | +$4M | $4M |
| GOLAR LNG LTD | NEW | +75.0K | 75.0K | +$3M | $3M |
| TEVATEVA PHARMACEUTICAL INDS LTD | NEW | +180.8K | 180.8K | +$3M | $3M |
| ALBALBEMARLE CORP | NEW | +34.0K | 34.0K | +$2M | $2M |
| ESTABLISHMENT LABS HLDGS INC | NEW | +56.2K | 56.2K | +$2M | $2M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2025
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $303M | 73 | May 12, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $425M | 62 | Feb 5, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $192M | 47 | Nov 4, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $216M | 70 | Aug 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $259M | 75 | May 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $153M | 55 | Feb 10, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $210M | 56 | Nov 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $275M | 68 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $272M | 75 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $239M | 67 | Feb 12, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $176M | 64 | Nov 15, 2023 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2023 | $203M | 70 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $195M | 81 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $174M | 95 | Feb 15, 2023 | RESTATEMENT | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.